Evidence map›Paper›PMID 30145817›Full record

Trial reportESC heart failure2018

Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.

Thor Ueland, Lars Gullestad, Lei Kou, Pål Aukrust, Inderjit S Anand, Marianne Nordlund Broughton, John J McMurray, Dirk J van Veldhuisen, David J Warren, Nils Bolstad

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Thor UelandResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Lars GullestadDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Lei KouCleveland Clinic, Cleveland, OH, USA.
Pål AukrustResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Inderjit S AnandVA Medical Center, University of Minnesota, Minneapolis, MN, USA.
Marianne Nordlund BroughtonDepartment of Medical Biochemistry, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
John J McMurrayBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Dirk J van VeldhuisenUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
David J WarrenDepartment of Medical Biochemistry, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Nils BolstadDepartment of Medical Biochemistry, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Oslo University Hospital · NOCleveland Clinic · USThrombosis Research Institute · GBUniversity of Glasgow · GBUniversity of Groningen · NLUniversity of Minnesota · USUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsNeuroendocrine activation is associated with poor outcome in heart failure (HF). The neuropeptide gastrin-releasing peptide (GRP), derived from the precursor proGRP1-125 (proGRP), has recently been implicated in inflammation and wound repair. We investigated the predictive value of proGRP on clinical outcomes in HF patients with reduced ejection fraction. METHODS AND

resultsThe association between plasma proGRP (time-resolved immunofluorometric assay) and the primary endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate anaemia, enrolled in the Reduction of Events by Darbepoetin alfa in Heart Failure (RED-HF) trial. Median proGRP levels in the RED-HF cohort were markedly increased [95 ng/L (25th, 75th percentile, 69-129 ng/L)] with 64% patients above the 80 ng/L reference limit. Baseline proGRP correlated with estimated glomerular filtration rate (r = 0.52), N terminal pro brain natriuretic peptide (r = 0.33), troponin T (r = 0.34), and haemoglobin (r = 0.16) (all P < 0.001). The incidence outcome increased with increasing tertiles of baseline proGRP (primary endpoint third tertile vs. the lowest tertile; hazard ratio 1.91; 95% confidence interval 1.60-2.28, P < 0.001). However, these associations were markedly attenuated and non-significant in adjusted models. No interaction between baseline proGRP and the effect of darbepoetin alfa treatment was detected. Moreover, no significant association between changes in proGRP during 6 month follow-up and outcome was observed.

conclusionsPro-gastrin-releasing peptide is increased in patients with HF with reduced ejection fraction and anaemia, in particular in patients with poor renal function. However, proGRP adds little as a prognostic marker on top of conventional HF risk factors.

Indexed as

AgedAnemiaBiomarkersDarbepoetin alfaDose-Response Relationship, DrugFemaleGastrin-Releasing PeptideHeart FailureHematinicsHumansInjections, SubcutaneousMaleMiddle AgedPrognosisStroke VolumeBiomarkersDarbepoetin alfaGastrin-Releasing PeptideHematinicsAnaemiaHeart failurePrognosisProGRP

Identifiers

PMID30145817
PMCPMC6300802
OpenAlexW2888666826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.